Overview

HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC

Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Zoledronic acid was initially used for bone metastases in various malignancies. However, it is unknown whether hepatic arterial infusion chemotherapy combined with zoledronic acid can improve overall survival of unresectable hepatocellular carcinoma.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
Zoledronic Acid